A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients

BACKGROUND: Currently, no vaccine against Pseudomonas is available. IC43 is a new, recombinant, protein (OprF/I)-based vaccine against the opportunistic pathogen, Pseudomonas aeruginosa, a major cause of serious hospital-acquired infections. IC43 has proven immunogenicity and tolerability in healthy...

Descripción completa

Detalles Bibliográficos
Autores principales: Rello, Jordi, Krenn, Claus-Georg, Locker, Gottfried, Pilger, Ernst, Madl, Christian, Balica, Laura, Dugernier, Thierry, Laterre, Pierre-Francois, Spapen, Herbert, Depuydt, Pieter, Vincent, Jean-Louis, Bogár, Lajos, Szabó, Zsuzsanna, Völgyes, Barbara, Máñez, Rafael, Cakar, Nahit, Ramazanoglu, Atilla, Topeli, Arzu, Mastruzzo, Maria A., Jasovich, Abel, Remolif, Christian G., del Carmen Soria, Liliana, Andresen Hernandez, Max A., Ruiz Balart, Carolina, Krémer, Ildikó, Molnár, Zsolt, von Sonnenburg, Frank, Lyons, Arthur, Joannidis, Michael, Burgmann, Heinz, Welte, Tobias, Klingler, Anton, Hochreiter, Romana, Westritschnig, Kerstin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5291979/
https://www.ncbi.nlm.nih.gov/pubmed/28159015
http://dx.doi.org/10.1186/s13054-017-1601-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5291979/
https://www.ncbi.nlm.nih.gov/pubmed/28159015
http://dx.doi.org/10.1186/s13054-017-1601-9

Ejemplares similares